At the news
? NEUTRALIMPACT 5/10 8-K filed Jun 16, 2026 at 07:00 ET
PTC Therapeutics priced $500M of 0% convertible senior notes due 2031 (plus a $50M greenshoe) to refinance its 1.5% 2026 notes. The company will use ~$328.8M of proceeds to repurchase $222M principal of the 2026 notes at a premium, extending maturities by five years at zero interest cost. The conversion price of $107.48 represents a 40% premium over the $76.77 closing price, limiting near-term dilution.
- $500M aggregate principal of 0% convertible senior notes due 2031 priced on June 15, 2026
- Initial purchasers granted a 13-day option for an additional $50M in notes
- Net proceeds estimated at ~$486.8M (or ~$535.5M if greenshoe fully exercised)
- ~$328.8M of net proceeds used to repurchase $222M principal of 1.5% 2026 notes via privately negotiated transactions
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access